USFDA accepts Shilpa Medicare CDMO partner Unicycive NDA for Oxylanthanum Carbonate Ruchika Sharma13 Nov 2024 12:13 PM ISTKarnataka: Shilpa Medicare CDMO partner Unicycive Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (USFDA) has...
Shilpa Medicare announces submission of NDA for Oxylanthanum Carbonate to USFDA by Unicycive Therapeutics Ruchika Sharma5 Sept 2024 11:20 AM ISTKarnataka: Unicycive Therapeutics, Inc. has announced the submission of New Drug Application (NDA) to United States Food and Drug Application...
Shilpa Medicare CDMO customer reports positive results from Oxylanthanum Carbonate trial Ruchika Sharma6 July 2024 11:30 AM ISTKarnataka: Shilpa Medicare Limited's CDMO customer, Unicycive Therapeutics, Inc. has reported positive results from pivotal clinical trial of...
USFDA grants appeal for Ardelyx XPHOZAH Ruchika Sharma1 Jan 2023 3:30 PM ISTXPHOZAH (tenapanor), discovered and developed by Ardelyx, is an investigational first-in-class phosphate absorption inhibitor (PAI).
FDA panel okays tenapanor as monotherapy for control of serum phosphorus in CKD patients on dialysis Dr. Kamal Kant Kohli18 Nov 2022 10:15 AM ISTUse of tenapanor (Xphozah®) as monotherapy for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis has...
Lanthanum carbonate Vs Calcium Carbonate for Hyperphosphatemia: JAMA Dr Kartikeya Kohli21 May 2021 10:59 AM ISTHyperphosphatemia is a significant factor associated with cardiovascular events and all-cause death among patients with chronic kidney disease (CKD)....
Strict Phosphate Control Delays CAC Progression In Patients On Hemodialysis, EPISODE Trial Dr Kartikeya Kohli18 April 2021 11:30 PM ISTIn patients on maintenance dialysis, cardiovascular mortality risk is remarkably high, which can be partly explained by severe coronary artery...
Phosphate lowering diet promising therapy for patients on dialysis: Study Medha Baranwal15 Jan 2021 9:45 AM ISTUSA: Monthly diet therapy focused on lowering serum phosphate levels may be safe and effective for the treatment of persistent hyperphosphatemia...
Bone fracture risk may increase when critical enzymatic processes decline Hina Zahid8 Jan 2021 3:56 PM ISTTROY, N.Y. - A loss of enzymatic processes within the body can increase a person's risk of bone fracture. This new insight was recently published in...
